All articles by Adam Zamecnik

Adam Zamecnik is a healthcare reporter for Pharmaceutical Technology. He has covered diverse topics such as continuous drug manufacturing, genomic research and sexual health. He is particularly interested in new technologies, health inequality, and cell and gene therapy research.

Adam Zamecnik

@a_zamecnik
Features

Regulatory roundup: Ascendis’ shot at further study in achondroplasia jumps

Secura Bio in peripheral T-cell lymphoma is also reviewed by GlobalData’s Investigative News team.

Features

ASH hot topic: site selection key in reducing disparity in cancer trials

Using trial locations that represent a disease’s epidemiology can assuage recruitment hurdles and would better represent the drug’s potential real-world use.

Features

Regulatory roundup: Xenon’s shot at further study in focal epilepsy leaps after positive Phase IIb

Aeglea’s pegzilarginase and Neurocrine in movement disorders are also reviewed by GlobalData’s Investigative News team.

Features

Regulatory roundup: Veru’s likelihood of further study in vasomotor symptoms jumps after Phase II completion

SAB Therapeutics in influenza A and Ocular Therapeutix in keratoconjunctivitis sicca is also reviewed by GlobalData’s Investigative News team.

Features

Timing of Synairgen Phase III nebulised Covid-19 treatment remains a challenge

There are also concerns surrounding Synairgen SNG001’s potential inflammatory effects in advanced Covid-19.

Company News

SyneuRx to recruit 500–1,000 patients for oral Covid-19 antiviral Phase III test

The US-based Phase III will likely use electronic Patient Report Outcome (ePRO) tools to report symptoms.

Features

Wet AMD: Kodiak asset faces tough comparator Eylea in late-phase test

Kodiak’s Phase IIb/III asset KSI-301 may have a possible market edge in terms of contraindication and spread out dosing if approved.

Features

Can Rigel’s bleeding disorder drug fostamatinib cross over into Covid-19?

Experts are optimistic of fostamatinib’s potential in hospitalised Covid-19 though they note available data is from a 59-patient trial.